World’s First MAGE-A4-Targeting TCR-NK Therapy Zelluna Doses First Patient in Clinical Trial
Zelluna ASA, a Norwegian biotech company pioneering allogeneic cell therapies for solid cancers, recently announced that the first patient has received the first dose of ZI-MA4-1 in the ZIMA-101 Phase 1 clinical trial. The treatment was administered at The Christie NHS Foundation Trust in Manchester, United Kingdom, the largest single-site cancer centre in Europe, marking a significant milestone not just for Zelluna but for the broader synovial sarcoma community.
What Makes This Different
ZI-MA4-1 is the world’s first MAGE-A4-targeting TCR-NK (T Cell Receptor-based Natural Killer) cell therapy to enter clinical development. What sets it apart from other cell therapies in the synovial sarcoma space is its off-the-shelf design. Rather than requiring a patient’s own cells to be collected, engineered, and reinfused, ZI-MA4-1 uses donor-derived NK cells that are pre-engineered with an affinity-optimized TCR to recognize and attack MAGE-A4-expressing tumors. This approach has the potential to be faster, more scalable, and more accessible than existing personalized cell therapies.
The therapy targets MAGE-A4, a protein expressed across several cancer types including synovial sarcoma, ovarian cancer, squamous non-small cell lung cancer, and head and neck cancer. In synovial sarcoma specifically, MAGE-A4 has emerged as one of the most clinically actionable targets, already validated through the FDA approval of Tecelra (afamitresgene autoleucel).
About the Trial
ZIMA-101 is a first-in-human, multicenter Phase 1 dose-escalation study evaluating the safety, tolerability, and early anti-tumor activity of ZI-MA4-1 in patients with advanced MAGE-A4-positive solid tumors. The study follows a 3+3 dose escalation design with three predefined dose levels. Each patient receives three doses on Days 1, 4, and 8 of a treatment cycle. An Independent Data Monitoring Committee reviews safety data before additional patients are enrolled at each dose level. The study is currently active at two UK sites: The Christie NHS Foundation Trust and The Royal Marsden NHS Foundation Trust.
Chief Investigator Professor Fiona Thistlethwaite, Consultant Medical Oncologist at The Christie and Honorary Professor at the University of Manchester, noted that dosing the first patient “represents an exciting moment for everyone who has worked collaboratively to bring this brand-new class of cellular therapy to the clinic.” Zelluna expects initial clinical data to emerge from mid-2026.
What This Means for the SS Community
For synovial sarcoma patients, the ZIMA-101 trial represents another meaningful step forward in the growing landscape of targeted cell therapies. The approval of Tecelra (afamitresgene autoleucel) was a historic milestone for the synovial sarcoma community, establishing MAGE-A4 as a validated and actionable target in this disease. ZI-MA4-1 now aims to expand on that progress by exploring whether an off-the-shelf NK cell approach can deliver similar MAGE-A4-directed activity with the added potential of faster access and broader availability.
The trial is currently enrolling at UK sites. You can learn more about the trial here and visit our clinical trials and therapies page for information on active trials.
You can access the original publication here. For more information about the Synovial Sarcoma Foundation, please visit our website.
